Side Effects of Sublinox 5 mg
Sublinox (sublingual zolpidem) 5 mg carries risks of psychiatric adverse events, memory impairment, driving impairment, fractures, and complex sleep behaviors, though most adverse effects in clinical trials were mild to moderate. 1
Common and Mild-to-Moderate Side Effects
In clinical trials, sublingual zolpidem formulations were generally well tolerated with most adverse events being mild or moderate in severity 2. The overall tolerability profile of sublingual zolpidem was similar to oral zolpidem 2. Withdrawal rates due to adverse effects were modestly higher than placebo (6% versus 3%) 1.
Recent real-world data from 2025 showed that among zolpidem users, 55.4% reported experiencing adverse reactions, with the most commonly reported being:
- Amnesia
- Paradoxical insomnia
- Sleepwalking 3
Continuous use and younger age were significantly associated with higher rates of adverse reactions 3.
Serious and Life-Threatening Risks
Cognitive and Behavioral Impairments
FDA data indicates zolpidem causes higher incidence of psychiatric adverse events, memory impairment, and driving impairment 1. These include:
- Complex sleep behaviors: Sleep-driving, sleep-walking, and other activities while not fully awake 1, 4
- Amnesia and confusion 1, 4
- Hallucinations 4
- Increased suicidality: OR 2.08 (95% CI 1.83-2.63) regardless of psychiatric comorbidity 4
Falls and Fractures
Zolpidem significantly increases fracture risk with an adjusted odds ratio of 1.72 (95% CI 1.37-2.16) 1. Hospitalized patients face an OR of 4.28 (P<0.001) for falls when prescribed short-term 4. Hip fractures are most common with a relative risk of 1.92 (95% CI 1.65-2.24) 4.
In older patients specifically, sedative-hypnotics cause:
- 5-fold increase in memory loss, confusion, and disorientation
- 3-fold increase in dizziness, loss of balance, or falls
- 4-fold increase in residual morning sedation 1
Next-Morning Impairment
The critical concern is residual drug effects interfering with morning activities, particularly driving. For sublingual zolpidem 3.5 mg taken middle-of-the-night, driving impairment was present at 3 hours but resolved by 4 hours post-dose 5. The 5 mg dose recommended for women was specifically implemented due to slower drug clearance and higher morning blood concentrations in women compared to men 6.
Long-Term Risks
Observational studies suggest associations with:
- Major head injury or fracture requiring hospitalization: adjusted HR 1.67 (95% CI 1.19-2.34) 1
- Incident cancers (though evidence is inconsistent) 1
- Increased all-cause mortality (inconsistent results across studies) 1
- Dementia 1
Withdrawal and Dependence
- Rebound insomnia: Sleep onset latency significantly increased by 13.0 minutes (95% CI 4.3-21.7) on first night after stopping 4
- Withdrawal seizures: Reported even at doses as low as 160 mg/day cumulative use 4
- Tolerance and dependence potential 1
Critical Clinical Pitfalls
The 5 mg dose is specifically FDA-recommended for women due to sex differences in metabolism 6. Women have approximately 35% lower clearance than men (236 vs 364 mL/min, P<0.001), leading to higher morning drug levels 7.
Avoid use in:
- Elderly or debilitated patients (higher fall risk)
- Patients who must drive or operate machinery within 4 hours of dosing
- Those with depression (increased suicide risk)
- Pregnancy (Category C: increased low birth weight, preterm delivery, small for gestational age babies) 4
Monitor for complex sleep behaviors which can occur regardless of dose, age, medical history, or prior sleepwalking history 4.